iPSC

#Cell culture #Drug development #Drug discovery #Guide #iPSC

New Guide: How to get the best out of your neurons

A new Guide is now available entitled ‘Four cell culture hacks to get the best out of your neurons’, sponsored by bit.bio. Make your iPSC-derived glutamatergic neuron cultures a success every time with these tips from a neuronal cell culture expert. Download the Guide to learn: How to prevent glutamatergic… Read More

#News

#Cell culture #Drug development #Drug discovery #Guide #iPSC

Four cell culture hacks to get the best out of your neurons

Make your iPSC-derived glutamatergic neuron cultures a success every time with these tips from a neuronal cell culture expert. In this Guide, you will learn: How to prevent glutamatergic neurons from detaching from culture surfaces How to formulate extracellular matrix coatings to promote cell adherence The best timings for media… Read More

#Intelligence #Resources

#Biopharma #Infographic #iPSC

Infographic: Differentiating iPSCs – Which Approach Works Best?

Current methods to generate cells from human-induced pluripotent stem cells (iPSCs) lack reproducibility and scalability. This raises challenges for disease research, drug discovery and cell therapy development due to unreliable data and long experimental timelines. However, there is a new technology on the block, enabling reproducible, consistent and scalable production… Read More

#News

#Autoimmune disease #iPSC #Stem cells

New human beta cell model enables discoveries in diabetes research 

Human Cell Design, a biotechnology company focused on generating translational human cellular models, has launched Endoc-BH5 to “open up entirely new scientific avenues in diabetes studies”, the company says.   What is Endoc-BH5?  Human Cell Design combined hiPSC-derived differentiated cells (human-induced Pluripotent Stem Cells) and primary… Read More

#News

#Drug discovery #Eye health #iPSC #Ophthalmology #Partnership

Evotec enters ophthalmology drug discovery partnership 

Evotec has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (iPSC)-based disease modelling for ophthalmologic disorders.   Context   Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. … Read More

#News

#Assays #Biotechnology #Cell and gene therapy #Cell therapy #iPSC

Ncardia secures $60+ million for its iPSC Offerings 

Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform.  Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening. … Read More

#News

#Collaboration #iPSC #Neuroscience

Neuroscience collaboration expands to include novel cell type 

Evotec has expanded its collaboration with Bristol Myers Squibb to include a new cell type.  The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’… Read More

#News

#Drug discovery #iPSC #Stem cells #Therapeutics

Therapeutics research partnership to access induced Pluripotent Stem Cells 

Bone Therapeutics and Implant Therapeutics have signed a research evaluation agreement to enable Bone Therapeutics to access, evaluate and materially transfer Implant Therapeutics’ Induced Pluripotent Stem Cell (iPSC) lines, media, differentiation protocols and expertise.  Bone Therapeutics has developed a bone marrow-derived off-the-shelf, allogeneic MSC cell therapy platform. Read More

#News

#Biomedical research #Drug discovery #iPSC #Synthetic biology

Sitting down with…bit.bio

bit.bio is a synthetic biology company working on producing every human cell type at scale, with the aim of transforming the research and medicine landscape. Farah Patell-Socha, PhD, VP Research Products tells Lu Rahman about some of the company’s groundbreaking work in this field and the benefits it is creating… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biologics / Biotechnology #Biotechnology #iPSC

Axol Bioscience and Censo Biotechnologies announce merger

Axol Bioscience, provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies,  have signed a merger agreement. The new entity will become a provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modelling for… Read More

#News

#Gene editing #iPSC #Therapeutics

Horizon applies expertise for iPSC cell line engineering services

The development of therapeutic treatments is a challenging process linked to understanding mechanisms that underly human disorders. Finding the relevant biological model has been a limiting process so far. The development of induced pluripotent stem cell (iPSC) technology has revolutionised the way we study complex disorders. iPSCs offer a unique… Read More

#News